Dr. Yi (Gloria) Wang is the Chief Medical Officer of TASLY Biopharmaceutical Co., Ltd. She has more than 15 years’ experience in clinical development for novel products including small chemical compound, monoclonal antibody, recombination protein and therapeutic cellular products such as CAR-T and stem cells. She is also good at life cycle management for the pharmaceutical products. She initiated her career in medical development in Johns Hopkins University when she worked as a full-time employee here. After entered the pharmaceutical industry she worked in Novartis and United Therapeutics Corporation et al. She led her team conducted several multiple regional clinical trials in in America, Europe and Asia-Pacific Areas and launched the products in the major markets worldwide. Dr. Wang has her M.D. from Tongji University and Ph.D. from Fudan University. She received her postdoctoral trainings from University of Massachusetts Medical School.